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Abstract 
    Osteoporosis is a common disease in elderly which is defined as a low bone mineral 
density (BMD) and easy to undergo bone fractures. Bone fractures reduce QOL and life 
expectancy of osteoporosis patient so that preventing bone fractures is the aim of 
osteoporosis treatment. However, not a few people broke their bones even under adequate 
osteoporosis treatments. So, establishment of more effective osteoporosis treatment to 
prevent bone fractures are required. Active vitamin D3 (VD3) analogs and bisphosphonates 
(BPs) are used for osteoporosis treatment. Active VD3 and BPs reduced bone resorption and 
corrected excessive bone turnover. BPs bind to bone surface and are incorporated into 
osteoclast during bone resorption so that induce apoptosis of osteoclasts. However, the 
mechanisms of anti-bone resorptive effects of active VD3 had not been elucidated. In this 
study, I demonstrated that active VD3 directly inhibited osteoclastogenesis via IFN-β 
cascade. Active VD3 increased IFN-β expression at the early stage of osteoclastogenesis and 
inhibited human bone marrow derived osteoclast progenitor cells. Antibody against IFN-β 
diminished the inhibitory effect of active VD3 on inhibition of osteoclastogenesis. And 
inhibitory effect of VD3 on osteoclastlgenesis was also reduced in IFN-β receptor deficient 
mice osteoclast progenitor cells. In rat model for postmenopausal osteoporosis, combination 
treatment of early phase osteoclastogenesis inhibitor active VD3 and late phase inhibitor BP 
showed a synergistic effect on bone strength through reduction of bone resorption. 
Interestingly, different from an additive effect on reduction of bone resorption, combination 
treatment with active VD3 and BP exhibited no difference in bone formation between 
monotherapy and combination therapy. My findings of molecular mechanisms of inhibitory 
effect of active VD3 on osteoclast differentiation and in vivo effects of combination therapy of 
active VD3 and BP with additive effect on reducing bone resorption without severe 
suppression of bone formation may help us to investigate the effective treatment of 
osteoporosis using active VD3. 
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Abbreviations 
 
ADL : activity of daily living  
ALF : alfacalcidol  
ALN : alendronate  
AP-1 : activator protein-1  
BMD : bone mineral density  
BP : bisphosphonate  
CFU-GM : granulocyte macrophage colony forming units  
DXA : dual-energy X-ray absorptiometry 
ELD : eldecalcitol 
ES/BS : erosion surface per bone surface 
c-Fos : c-FBJ osteosarcoma  
GM-CSF : granulocyte macrophage colony-stimulating factor 
IFN : interferon 
IL-3 : interleukin-3 
M-CSF : macrophage colony-stimulating factor 
MS/BS : mineralizing surface per bone surface 
NFATc1 : nuclear factor of activated T cells c1 
NF-κB  : nuclear factor κB 
OPG : osteoprotegerin 
OVX : ovariectomized 
QOL : quality of life 
RANK : receptor activator of NF-κB 
RANKL : RANK ligand 
SFC : stem cell factor 
TNF : tumor necrosis factor 
VD3 : vitamin D3 
VDR : vitamin D receptor 
VDRE : vitamin D response element 
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General Introduction 
 
  Osteoporosis is a common disease in elderly which is defined as a low bone mineral 
density (BMD) and easy to undergo bone fractures. It is estimated, over 80 years old, about a 
half in women and ten percent of men have non-traumatic bone fractures or low BMD less 
than 70% that of young adult mean (Yoshimura et al. 2010) and diagnosed as osteoporosis. 
It is well known that bone fractures affect life prognosis or activity of daily living (ADL) in 
elder people, therefore the prevention of bone fracture with osteoporotic treatment has 
benefits not only in bone itself but also in a quality of life (QOL) in elder people.  
  Bone is a dynamic tissue so that old bone matrix are replaced by new bone component. 
The matrix are resorbed by osteoclasts, which are differentiated from monocytes, and 
re-constructed by mesenchymal osteoblasts. Bone resorption by osteoclast releases bone 
forming molecules from bone matrix which as IGF-1, and stimulates osteoblast 
differentiation and bone formation. Not only secreted molecules from bone matrix, 
cell-to-cell interaction with osteoblast, for example, interaction of ephrinB2-EphB4 also 
stimulate bone matrix production (Zhao et al. 2006). On the other hand, activated osteoblast 
stimulates osteoclastogenesis or bone resorption by osteoclasts. Osteoblasts express receptor 
activator of NF-κB (RANK) ligand (RANKL) on its membrane or secrete soluble form of 
RANKL. RANKL binds to RANK on osteoclast surface and stimulates osteoclast 
differentiation or bone resorption. RANKL-RANK signal stimulates transcription factors 
such as nuclear factor κB (NF-κB) and c-FBJ osteosarcoma (Fos) which a component of 
activator protein 1 (AP-1). NF-κB and AP-1 induce upregulation of transcription factor 
nuclear factor of activated T cells (NFAT) c1. NFATc1 is a key transcription factor to 
activate osteoclast differentiation and bone resorption. So, bone resorption by osteoclast 
induces osteoblast differentiation and stimulation, and stimulated osteoblasts induce 
osteoclastogenesis. This bone resorption and formation cycle is called “remodeling”. 
 Postmenopausal osteoporosis is induced by accelerated bone resorption because of estrogen 
deficiency. The lack of estrogen signaling in osteoclast results in prolongation of its life span 
and increases number of osteoclasts and activates bone resorption (Nakamura et al. 2007). 
Activated bone resorption accelerates bone formation. This excessive remodeling cycle result 
in bone loss, because bone formation required much more time than bone resorption so that 
bone formation can not catch up with bone resorption in high bone turnover situations.  
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  For osteoporosis treatment, various drugs are used. Among them, anti-bone resorptive 
drugs are mainly used. BPs are most popular drugs in this field. BPs bind to bone surface 
and incorporated into osteoclast during bone resorption. BPs induce apoptosis of osteoclast 
to inhibit bone resorption. Because BPs effect is so strong, sometimes bone remodeling 
suppressed severely. A low bone remodeling turnover accumulate micro damages in bone 
and it is considered as a cause of atypical fracture. Atypical fracture occurs suddenly in 
femoral midshaft in patients who received a long term BPs medication.  
  Active VD3 analogs are other anti-bone resorptive drugs. In addition to the effect on 
reduction of bone resorption, active VD3 analogs increase calcium absorption of small 
intestine so that support bone formation. Though active VD3 and its analogs reduce bone 
resorption and increases BMD in animals or osteoporosis patients, the role of active VD3 in 
osteoclast differentiation is not fully understood.  
  Bone fractures in elderly accompanied by other dysfuctions. Lumbar fractures cause 
bending posture and intestinal mal-function. Fractures of femurs are the major cause of 
bedridden and reduction of life expectancy. Therefore, preventing bone fracture is important 
not only for activity of daily living (ADL) but quality of life (QOL). In present osteoporosis 
treatment, not a few bone fractures occurred in the patients who undergo osteoporosis 
treatment so that more effective treatment to prevent bone fractures would be desired. 
  In this study, I investigated the effect of active VD3 on osteoclast differentiation using 
human bone marrow-derived osteoclast precursor cells, and elucidated the molecular 
mechanism of the direct effect of active VD3 on human osteoclastogenesis. Next, I revealed 
that the effectiveness of osteoporosis treatment with VD3 derivative, eldecalcitol (ELD), and 
BP, alendronate (ALN), which has different mechanism on osteoclastogenesis inhibition, 
using a rat osteoporosis model.  
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Chapter 1 
Active VD3 inhibits human osteoclastogenesis directly via IFN-beta. 
 
  One-Alpha, 25-dihydroxy vitamin D3 [1α,25(OH)2D3], an active form of VD3, plays a 
critical role in calcium and bone metabolism. Although active VD3 decrease osteoclast 
number and bone resorption of osteoporosis patients, the action of active VD3 on 
osteoclastogenesis is still unclear. Besides usage for anti-bone resorptive drug on 
osteoporosis, VD3 are used to obtain osteoclast in osteoblast-monocyte co-culture system. 
Osteoclast precursors express RANK, a receptor of RANKL, and RANKL-RANK signaling 
stimulates osteoclast differentiation. The active VD3 upregulates a expression of RANKL in 
osteoblasts and enhances osteoclastgenesis of monocyte in co-culture. Therefore, there is a 
discrepancy of active VD3 actions between anti-bone resorptive effect in vivo and 
enhancement of osteoclastogenesis in vitro. So it is important to elucidate the precise effect 
of active VD3 on osteoclast differentiation to investigate the effective approach to 
osteoporosis therapy. 
  In osteoporosis patients, the expression of RANKL is abundant in osteoblasts and  
bone resorption-formation remodeling cycle is highly accelerating. To estimate the effect of 
active VD3 on osteoclastogenesis in the circumstance of osteoporosis patients in vitro, the 
active VD3 effect should be assessed in osteoclastogenesis accelerating condition, in other 
words, monocyte monoculture stimulate with abundant RANKL protein. For this purpose, I 
investigate the effect of active VD3 on osteoclastogenesis in human bone marrow derived 
monocyte stimulated with RANKL. Human monocytes differentiated into osteoclast in 
medium with abundant RANKL which mimic the accelerating circumstance of high bone 
turnover in osteoporosis patients and active VD3 was added in the medium to asses its effect 
on osteoclastogenesis. 
  Here I show that active VD3 significantly inhibited human osteoclast formation at the 
early stage of differentiation in a concentration-dependent manner. Active VD3 upregulated 
the expression of interferon-β (IFN-β), a strong inhibitor of osteoclastogenesis in osteoclast 
progenitors. Inhibitory effects of active VD3 on osteoclastogenesis was diminished by 
treatment with a neutralizing antibody against IFN-β. And bone marrow of IFN-β receptor 
deficient mice are partially resistant to active VD3 treatment. Thus, my study may provide a 
molecular basis for the treatment of human bone diseases by active vitamin D3 through 
regulation of the IFN-β.  
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Introduction 
  Bone is rigid tissue consist of bone matrix and minerals. And bone is constantly renewed 
by bone resorbing osteoclasts and bone forming osteoblasts. This bone resorption-formation 
cycle called bone remodeling. Bone remodeling helps to maintain the bone integrity to repair 
damages. It is considered that bone formation was caused by bone formation stimulating 
molecule which is released from resorbed bone matrix or secreted from osteoclasts. 
Osteoporosis is defined as low BMD and fragility of bone. In osteoporosis patients, both bone 
resorption and bone formation are accelerated. This excessive bone resorption and formation 
cycle called “high bone turnover”. Though bone formation is activated, high bone turnover 
result in bone loss because bone resorptoin is much faster than bone formation. So inhibition 
of bone resorption is a main strategy for osteoporosis treatment.   
  Osteoclasts are bone-resorbing multinuclear cells derived from hematopoietic stem cells 
(Miyamoto et al. 2003). Recent studies have shown that the interaction between receptor 
activator of nuclear factor kappa-B (RANK) and RANK-ligand (RANKL) is essential for 
osteoclast differentiation and activation (Yasuda et al. 1998, Kong et al. 1999, Dougall et al. 
1999). RANK signaling stimulates tumor necrosis factor (TNF) receptor-associated factor 6 
(TRAF6) and c-Fos, a component of the AP-1 transcription factor complex, which in turn 
activates various downstream molecules such as tartrate-resistant acid phosphatase (TRAP) 
(Naito et al. 1999, Takayanagi et al. 2002a) (Figure 1). c-Fos is an essential transcription 
factor for osteoclast differentiation, and mice deficient in c-Fos exhibit a complete lack of 
osteoclast formation and severe osteopetrosis (Johnson et al. 1992). Nuclear factor of 
activated T cells (NFAT) 2, also called NFATc1, is a downstream transcription factor of 
c-Fos in the RANKL/RANK axis and is also essential for osteoclastogenesis (Matsuo et al. 
2004, Asagiri et al. 2005). Although c-Fos positively regulates osteoclast differentiation by 
inducing NFATc1 and Fos-related antigen (Fra)-1, both of which are essential transcription 
factors for osteoclast differentiation (Takayanagi et al. 2002a, Matsuo et al. 2004, Matsuo et 
al. 2000), it also induces interferon-beta (IFN-β), a strong inhibitor of osteoclast 
differentiation, and it negatively regulates osteoclastogenesis through one of the 
IFN-α/βreceptor components, IFNAR1, in a negative feedback manner (Takayanagi et al. 
2002b). 
  Patients with osteoporosis exhibit excessive bone resorption as a consequence of 
accelerated osteoclast differentiation and activation. A depletioln of estrogen signaling, 
lifespan of osteoclasts are elongated result in acceleration of  one resorption (Nakamura et 
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al. 2007). Extensive bone resorption brings immature bone formation, which results in 
decreased BMD and attenuated bone strength. Administration of active VD3 analogues to 
osteoporosis patients reduces bone resorption and bone fracture frequency (Sairanen et al. 
2000, Aloia et al. 1988). Ovariectomized rodents have been utilized as models of 
postmenopausal osteoporosis, and treatment with active VD3 analogues has been 
demonstrated to reduce osteoclast formation and bone resorption, thereby increasing BMD 
and bone strength in vivo (Shiraishi et al. 2000, Uchiyama et al. 2002). Interestingly, active 
VD3 has been used to induce osteoclast formation in a coculture system of bone marrow  
and osteoblastic cells. It has been shown that active VD3  acts on osteoblasts to upregulate 
the expression of RANKL, an essential trans-membrane ligand for osteoclastogenesis, while 
downregulating the expression of osteoprotegerin (OPG), a decoy receptor of RANKL that 
prevents osteoclastogenesis (Yasuda et al. 1998). Thus, active VD3 has been considered to be 
an osteoclast-inducing factor, although it inhibits osteoclast formation and increases BMD 
in osteoporosis patients.  
  In this study, I show that human osteoclastogenesis induced by macrophage 
colony-stimulating factor (M-CSF) and RANKL from bone marrow-derived osteoclast 
progenitor cells was strongly inhibited by active VD3 at an early stage of differentiation in a 
concentration-dependent manner. Active VD3 treatment upregulated IFN-β expression in 
osteoclast progenitor cells. The inhibitory effect of active VD3 on human osteoclastogenesis 
was restored by addition of an antibody against IFN-β. And bone marrow cells of IFN-β 
receptor deficient mice are partially resistant to active VD3 treatment. Thus, my data 
suggest a molecular basis for the treatment of activated osteoclast-induced bone diseases 
such as osteoporosis by active VD3 through the upregulation of IFN-β in the early stage of 
osteoclast differentiation. The elucidation of the effect of active VD3 on osteoclastogenesis 
may help us to investigate a effective treatment of osteoporosis.  
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Materials and methods 
 
Isolation of human bone marrow CFU-GM cells 
	 	 The study was approved by an Institutional Ethical Review Board (Keio Hospital 
#16-17-1), and informed consent was obtained from all study subjects. Human bone 
marrow-derived colony-forming unit granulocyte macrophage (CFU-GM) cells were 
generated as follows. Human bone marrow was obtained from patients undergoing routine 
hip replacement surgery. Cells were diluted 1:1 with Dulbecco’s phosphate-buffered saline 
(Invitrogen, Carlsbad, CA, USA) and filtered through a 70-µm nylon mesh cell strainer (BD 
Bioscience, Franklin Lakes, NJ, USA). The cell suspension was carefully layered on 
histopaque-1077 (Sigma-Aldrich, St. Louis, MO, USA) and centrifuged at 440g for 30 min at 
room temperature. The cell layer at the interface was transferred into a fresh tube as bone 
marrow mononuclear cells. Bone marrow mononuclear cells were cultured in 
methylcellulose semisolid medium (MethoCult H-4534; Stem cell Technologies, Vancouver, 
BC, Canada) containing 1% methylcellulose, 30% fetal bovine serum (FBS), 1% bovine 
serum albumin, 10–4 M 2-mercaptoethanol, 2 mM L-glutamine, 50 ng/mL recombinant 
human (rh) stem cell factor, 10 ng/mL rh GM-CSF, and 10 ng/mL rh IL-3 in 35-mm Petri 
dishes. Cultures were maintained in a humidified atmosphere at 5% CO2 at 37°C for 2 
weeks to obtain CFU-GM cells. 
 
Osteoclast differentiation of human CFU-GM cells 
	 	 Human CFU-GM cells were seeded in 96-well plates (2.0 × 104 cells/well) and cultured 
for 6 days in alpha-minimum essential medium (α-MEM) supplemented with 10% FBS, 30 
ng/mL M-CSF (Wako, Osaka, Japan) and 30 ng/mL RANKL (Wako) in the absence or 
presence of 10–10 M, 10–9 M, 10–8 M 1α,25(OH)2D3 (Wako). To examine the role for IFN-β in 
osteoclastogenesis of human CFU-GM cells, 500 unit/mL sheep polyclonal antibody against 
human IFN-β (PBL Biomedical Laboratories, New Brunswick, NJ, USA) was added in the 
culture medium. The culture medium was changed to fresh medium every other day. 
Osteoclastogenesis was evaluated by TRAP staining as described below. 
 
Tartrate-resistant acid phosphatase (TRAP) staining 
  Cultured cells were fixed with 10% formalin in PBS for 10 min at room temperature. After 
treatment with ethanol/ acetone (50:50 vol/vol) for 1 min, the cells were air dried and 
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incubated for 30 min at room temperature with TRAP-staining solution: 0.1 M sodium 
acetate (pH 5.0) containing 0.01% naphthol AS-MX phosphate (Sigma-Aldrich) as a 
substrate, and 0.03% red violet LB salt (Sigma-Aldrich) as a stain for the reaction product in 
the presence of 50 mM sodium tartrate. TRAP-positive multinuclear cells containing more 
than three nuclei were counted as osteoclasts. 
 
RNA extraction, RT-PCR, and quantitative real-time PCR analysis 
  Total RNA was isolated from osteoclast progenitors or osteoclasts using an RNeasy Mini 
kit (Qiagen, Valencia, CA, USA), and total RNA was reverse transcribed using Reverscript 
IV (Wako). Reverse transcription-polymerase chain reaction (RT-PCR) analysis was 
performed using the following primer sets: IFN-β, 5’-TCA TCT AGC ACT GGC TGG AA-3’–
5’-TTT CAA AAT CTT CTA GTG TCC TTT CA-3’ ; b-actin, 5’-TCC TGT GGC ATC CAC GAA 
ACT A-3’-5’ -CTC GGC CAC ATT GTG AAC TTT G-3’. PCR reactions were performed using 
TITANIUM Taq PCR Kit (Clontech, Mountain View, CA, USA). 
 
Osteoclast differentiation of mouse bone marrow cells 
All mice were maintained under pathogen-free conditions and cared for in accordance with 
the guidelines of Keio University School of Medicine. Bone marrow cells were isolated from 
8- to 12-week-old IFN-α/βreceptor 1 (IF-NAR1)-deficient or wild-type mice and cultured in 
α-MEM supplemented with 10% FBS for 5h. Non-adherent cells were harvested as 
osteoclast progenitor cells, seeded in 96-well plates (2.0 × 104 cells/well), and cultured for 6 
days in α-MEM supplemented with 10% FBS, 30 ng/mL M-CSF, and 30 ng/mL RANKL in 
the presence or absence of 1α,25(OH)2D3. The culture medium was changed to fresh medium 
on day 3. Osteoclastogenesis was evaluated by TRAP staining. 
 
Statistics 
  P values were calculated by unpaired Student’s t test. P values less than 0.05 were 
considered significant and are indicated by asterisks. 
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Results 
 
The effect of active VD3 on human osteoclastogenesis 
  I first asked whether active VD3 directly affects human osteoclastogenesis from osteoclast 
progenitor cells. Human osteoclast progenitor cells were prepared by cultivation of human 
bone marrow mononuclear cells in methylcellulose semisolid culture medium. Human 
osteoclastogenesis induced by M-CSF and RANKL in CFU-GM cells was significantly 
inhibited by active VD3 in a concentration-dependent manner (Figure 2A,2B), indicating 
that active VD3 inhibits osteoclast differentiation in human bone marrow-derived cells.  
  To understand the inhibitory mechanism of active VD3 on osteoclastogenesis, I subdivided 
the culture period into three parts (days 0–2, days 2–4, and days 4–6) to assess which stage 
was critical for inhibition of osteoclastogenesis by active VD3. Osteoclastogenesis was 
strongly inhibited when active VD3 was added to the culture medium at the earlier stage of 
differentiation (Figure 2C), which suggests that active VD3 affects molecules that act at an 
early rather than a later period of osteoclast differentiation in the presence of M-CSF and 
RANKL. 
 
IFN-β expression in osteoclast progenitor cells stimulated with active VD3 
  Next, I tried to elucidate the mechanism underlying inhibition of osteoclastogenesis by 
active VD3. I found that the expression of IFN-β, a strong inhibitor of osteoclastogenesis 
(Takayanagi et al. 2002b), was significantly upregulated by treatment with active VD3 in 
osteoclast progenitor cells (Figure 3A,3B). To analyze the role of IFN-β in the inhibition of 
osteoclastogenesis by active VD3, an antibody against IFN-β (500 unit/mL) was added to 
cultures with active VD3. Osteoclastogenesis inhibited by active VD3 was significantly 
restored by treatment with the antibody against IFN-β (Figure 3C), indicating that active 
VD3 negatively regulates osteoclastogenesis through the upregulation of IFN-β in osteoclast 
progenitor cells. 
 
The osteoclast differentiation of bone marrow cells from IFNARI-deficient mice stimulated 
with active VD3 
  I tried to confirm the inhibitory effect of active VD3 on osteoclastogenesis through an 
IFN-β cascade. To this end, I utilized an animal model deficient in IFNARI, one of the 
IFN-α/β receptor components, to inhibit the IFN-β-induced signals. The inhibition of 
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osteoclast differentiation by active VD3 was severe in wild-type cells compared with 
IFNARI-deficient cells (Figure 4). Taken together, my results demonstrate a novel 
mechanism of the direct inhibition of osteoclast differentiation by active VD3 through 
autocrine secretion of IFN-β. 
 
Active VD3 act to osteoclast progenitor cells and upregulated IFN-β expression and inhibited 
osteoclastogenesis  
  Finally, I investigated whether active VD3 can induce IFN-β and inhibit osteoclast 
differentiation in osteoclast progenitor cells which are not committed in osteoclast. Isolated 
CFU-GM were cultured in the medium with SCF, GM-CSF and IL-3, and active VD3 was 
added in the culture medium for 2 days. Cytokines and active VD3 were washed out and 
osteoclastogenesis was induced with M-CSF and RANKL. The osteoclastogenesis of 
CFU-GM was inhibited by active VD3 treatment (Figure 5A,5B). The IFN-β mRNA 
expression in CFU-GM cells was increased after 2-day’s active VD3 stimulation (Figure 5C). 
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Discussion 
  Because not a few people are insufficiet for VD3 nutrition among osteoporosis patients, the 
clinical effects of active VD3 analogues have been considered to occur via correction of active 
VD3 deficiency. However, a recent study reported that administration of active VD3 
analogues to osteoporosis patients under native VD3 supplementation also increased BMD 
(Matsumoto et al. 2005), suggesting that active VD3 and its analogues have antiosteoporotic 
effects in addition to correction of VD3 deficiency. Here I provide a possible mechanism 
underlying the antiosteoporotic effect of active VD3 in which active VD3 inhibits 
osteoclastogenesis by upregulating IFN-β expression. 
  Active VD3 downregulates PTH transcription in parathyroid cells (Okazaki et al. 1988, 
Demay et al. 1992) and upregulates intestinal calcium absorption, thereby prevents BMD 
reduction (Gallagher et al. 1979). In spite of its usage for osteoporosis therapy in humans, it 
was reported that active VD3 is an osteoclast-inducing factor in human cells (Takahashi et 
al. 1989). Active VD3 has also been used as an osteoclastogenesis-stimulating agent in 
co-cultures of murine osteoclast precursor cells with calvarial osteoblasts. Active VD3 
upregulates RANKL and downregulates the expression of OPG in osteoblasts (Yasuda et al. 
1998), and this reciprocal regulation of RANKL and OPG is critical for osteoclastogenesis. 
Thus, active VD3 has been considered to be an osteoclast-inducing factor through 
osteoblast-mediated activity. The regulation of the balance between direct inhibition of 
osteoclast progenitor cells by active VD3 and indirect stimulation of osteoclastogenesis 
through osteoblasts is still unclear, but my results suggest that administration of active VD3 
or its analogues to osteoporosis patients could directly inhibit osteoclastogenesis in 
circumstances with high bone turnover rates. In vitro experiment of human CFU-GM 
osteoclast precursor cells cultured with abundant RANKL mimics the circumstance of 
accelerating osteoclastogenesis in osteoporosis patients. My result showed the direct 
inhibitory effect of active VD3 on osteoclastgenesis through autocrine secretion of IFN-β in 
this circumstance. Active VD3 is a steroid hormone so that binds to its nuclear receptor, 
vitamin D receptor (VDR). Active VD3 and VDR complex binds to vitamin D response 
element (VDRE) in the target genes and controls is mRNA expression. Because I could not 
find any putative VDRE in 50-flanking region of the IFN-β gene, the regulation of IFN-β 
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expression by active VD3 is likely indirect. Further study is needed to elucidate the 
molecular mechanisms of the regulation of IFN-β expression by active VD3. 
  Here, I showed that active VD3 inhibited human osteoclastogenesis through IFN-β axis. 
This result may enhance the investigation of osteoporosis treatment using active VD3 and 
its analogs. 
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Chapter 2 
The effect of combination treatment of active VD3 and BP on bone remodeling in 
ovariectomized rats. 
 
  Eldecalcitol (ELD), an active VD3 analog, and alendronate (ALN), one of the nitrogen 
containing BPs are used for osteoporosis treatment because of its anti-bone resorptive 
effects. Osteoporosis is defined as a low BMD and bone fragility. The purpose of osteoporosis 
treatment is preventing bone fracture. However, not a few people under went bone fracture 
who receive appropriate osteoporosis treatment. The bone fractures induce low QOL and 
poor life expectancy so that establishment of more effective treatment for osteoporosis is 
required. I showed in chapter 1 that active VD3 inhibits the osteoclast differentiation at an 
early stage. On the other hand, BPs binds to bone surface and incorporated into osteoclast 
during bone resorption result in induction apotosis of mature osteoclast. I supposed that 
combination treatment of these two drugs which have different mechanisms in inhibition of 
bone resorption may exhibit superior effect on osteoporosis treatmet than mono-therapy of 
these drugs. To investigate this hypothesis, I administered either vehicle, ALN (0.2 mg/kg), 
ELD (15 ng/kg), or a combination of ALN and ELD to the ovariectomized (OVX) rats and 
measured bone strength and biological activities. The treatment started 2 weeks after 
surgery and continued for 12 weeks. A combination treatment of ELD and ALN showed 
significant increase in BMD of both lumber spine (L2-L4) and femur midshaft compared to 
mono-therapy groups. Erosion surface of lumber spine was reduced in ALN or ELD 
mono-therapy groups and the combination treatment group showed synergistic effect on 
erosion surface reduction. In endosteal surface of femur, only combination treatment group 
showed significant decrease in erosion surface. When it comes bone strength, combination 
treatment increased compression strength of lumber than both mono-therapy groups and 
3-point bending strength of femur than ALN mono-therapy group. 
  On the other hand, it is considered that “atypical fracture”, a bone fracture of femur 
midshaft without surgical trauma, is a consequence of “adynamic bone” which showed 
excessive reduction of bone turnover induced by strong inhibition of bone resorption by 
anti-bone resorptive agents. In combination treatment of ALN and ELD, different from 
synergistic effect on reduction of erosion surface, mineralize surface, a parameter for bone 
formation, in lumber were not changed in all three treatment groups suggested that this 
combination treatment regimen has mild effect on reduction of bone formation, while it 
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showed an additive effect on inhibition of bone resorption.  
  In conclusion, the combination treatment of ELD, an active VD3, and ALN, one of 
bisphosphonates, has synergistic effect on increasing in BMD and bone strength through the 
reduction of bone resorption without severe suppression of bone formation. This combination 
regimen for osteoporosis treatment may helpful in reduction of bone fracture frequency in 
osteoporosis patients without severe suppression of bone formation.   
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Introduction 
 
  Osteoporosis is characterized by a reduction in bone mass with age, contributing to a loss 
in bone strength (No authors 1991). 1α,25(OH)2D3 (active VD3) and its derivartives are used 
in osteoporosis treatment. Preclinical studies have shown clearly that active VD3 
metabolites can fully prevent estrogen deficiency-induced loss of cancellous and cortical 
bone by suppression of bone resorption (Erben et al. 1992, Erben et al. 1998, Shiraishi et al. 
2000, Weber et al. 2001). In OVX rat model of osteoporosis, the novel active VD3 derivative 
[ELD; 1α,25-dihydroxy-2β-(3-hydroxypro-pyloxy) vitamin D3] suppress bone resorption and 
increase bone mineral density (BMD) (Uchiyama et al. 2002). In osteoporosis patients, ELD 
suppresses bone resorption markers and increases lumbar and hip BMD following 1 year 
treatment (Matsumoto et al. 2005). A recent randomized, active comparator, double-blind 
study has shown that ELD has superior effects over alfacalcidol (ALF), a prodrug for active 
vitamin D3, in preventing vertebral and wrist fractures in osteoporotic patients with 
sufficient vitamin D supply, with a safety profile similar to that of ALF (Matsumoto et al. 
2011). In spite of the inhibitory effect on osteoclast differentiation in humans or animals, 
active VD3 increases the expression of RANKL from osteoblasts in vitro which activate a 
differentiation and bone resorptive activity of osteoclast. Because of this in vitro capacity of 
acceleration in osteoclast differentiation, I wondered how active VD3 reduce osteoclast 
number and bone resorption in vivo. In chapter 1, I demonstrated that active VD3 increased 
the expression of IFN-β in osteoclast precursor cells and inhibited osteoclastogenesis at the 
eary stage in RANKL abundant circumstance. My result made it possible to propose the 
regimens of osteoporosis treatment with combined medication with other bone resorptive 
drugs which have different mechanism to reduse bone resorption.  
  Bisphosphonates (BPs) such as alendronate (ALN) and risedronate are the most popular 
first-line drugs for the therapy of osteoporosis (Black et al. 1996, Harris et al. 1999). The 
target of BPs are mature osteoclasts because BPs binds to the bone surface and incorporate 
into mature osteoclasts during bone resorption. BPs are potent inhibitors of the bone 
resorptive capacity of mature osteoclasts and also may induce osteoclast apoptosis (Fleisch 
1998), and they prevent estrogen deficiency-induced bone loss in animals (Azuma et al. 1998, 
Ito et al. 2002).  
  In clinical, not a few bone fractures occured in the patients who receive appropriate 
osteoporosis treatments. The bone fractures worsen the QOL, ADL or life expectancy in 
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elder people so that establishment of more effective regimens of osteoporosis treatment are 
required to prevent bone fractures. As I demonstrated in chapter 1, active VD3 inhibits 
osteoclastogenesis at the early stage, on the other hand, BPs are absorbed into mature 
osteoclast and induce apoptosis of mature osteoclasts. The target cells of active VD3 and BPs 
are distinct from each other, so that the combination therapy of these two drugs may have 
an additive effect on reduction of bone fractures.  
  In this study, the effects of combination therapy of eldecalcitol (ELD), an active VD3 
derivative, and alendronate (ALN), a one of the nitrogen containing BPs, on BMD, bone 
strength and also physiological effects using OVX rat which is the model for post 
menopausal osteoporosis.  
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Materials and methods 
 
Reagents 
  1α,25-Dihydroxy-2β-(3-hydroxypropyloxy)vitamin D3 (eldecalcitol:ELD) and alendronate 
(ALN) were synthesized in our laboratories. ELD was dissolved in medium-chain 
triglyceride (MCT) and diluted to the given concentrations. ALN was dissolved in sterile 
physiological saline and diluted to the given concentrations. 
 
Animal experiments 
  The experimental protocol was approved by the Institutional Animal Care and Use 
Committee of Chugai Pharmaceutical Co., Ltd. 
Eight-month-old female Wistar–Imamichi rats were purchased from the Imamichi Institute 
for Animal Reproduction (Ibaraki, Japan). The rats were kept in individual stainless steel 
wire cages, and were allowed free access to standard commercial rodent chow (CE-2; CLEA 
Japan, Inc. Tokyo, Japan) and tap water. Animals were ovariectomized (OVX) or 
sham-operated (SHAM). Animals received daily doses of both vehicles (saline and MCT), or 
0.2 mg/kg of ALN and MCT, or 0.015 µg/kg of ELD and saline, or a combination of ALN and 
ELD. Both compounds and their vehicles were administered orally via gavage daily for 12 
weeks at a dose volume of 1 mL/ kg from 2 weeks after surgery. The dosage of each drug was 
selected based on that used clinically; 0.2 mg/kg and 0.015 µg/kg were comparable to the 
clinical dose for ALN and ELD, respectively. In order to prevent interference with ALN 
absorption, ELD or MCT vehicle was administered in the morning (between 08:00 and 
10:00) and ALN or saline was given in the afternoon (between 14:00 and 16:00). The body 
weight of each rat was measured weekly, After the administration of drug or vehicle at 12 
weeks, all rats were autopsied. and the lumbar vertebrae (L2–L5) and bilateral femurs were 
excised. The 5th lumbar vertebra (L5) and the left femur, which were used for measurement 
of mechanical strength, were stored frozen at −80 °C, and the other vertebrae (L2–L4) and 
right femur, which were used for measurement of BMD and bone histomorphometry 
parameters, were fixed in 70% ethanol. 
 
Measurement of mechanical properties 
  Using a mechanical strength analyzer (TK-252CC; Muromachi Kikai Co., Ltd., Tokyo, 
Japan), the mechanical strength of the lumbar vertebra (L5) and left femur was measured 
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using a compression test (Mosekilde et al. 1993) and a 3-point bending test (Katsumata et al. 
1995), respectively. For the compression test, planoparallel surfaces were obtained by 
removing the cranial and caudal ends of the vertebral specimen. From the vertebral body, a 
central cylinder with planoparallel ends and a height of approximately 5 mm was obtained. 
A compression force was applied to the specimen in a craniocaudal direction using a steel 
disk at a deformation rate of 2.5 mm/min. The ultimate compressive load (N) was  
calculated as the mechanical properties directly from the load–displacement curve. For the 
3-point bending test, the left femur was placed on a special holding device with supports 
located 12 mm apart. The bending force was applied with the cross head at a rate of 20 
mm/min, until a fracture occurred. From the load–displacement curve, the ultimate 
compressive load (N) was obtained. 
 
Measurement of bone mineral density 
  The average BMD (mg/cm2) of the lumbar vertebrae (L2–L4) was measured by 
dual-energy X-ray absorptiometry (DCS-600EX, Aloka Co., Ltd., Tokyo, Japan). The BMD of 
the right femur was measured with the DCS-600EX, with scans starting in the most 
proximal area and ending in the most distal area. During data analysis, the femur was 
divided into 10 equal segments (D1–D10) along its major axis. The mean values of the BMD 
for the 3 most proximal scanned areas (D1–D3), those for the next 4 scanned areas (D4–D7), 
and those for the 3 most distal areas (D8–D10) were calculated as the densities of the 
proximal, middle, and distal parts of the femur, respectively. 
 
Bone histomorphometry 
  The 3rd lumbar vertebral body (L3) and the diaphysis of the right femur were fixed in 70% 
ethanol, and stained according to the method of Villanueva (Villanueva 1974). After 
dehydration with ethanol and acetone, the samples were embedded in methyl methacrylate 
(Wako Pure Chemical Industries, Osaka, Japan). 
Midsagittal sections of L3, 5 µm thick, were obtained with a microtome (Supercut 2050; 
Reichert-Jung, Heidelberg, Germany) and prepared for measurement. A measuring field 
(~2.5 mm2) encompassing most of the cancellous bone in the L3 vertebra was used. The 
cancellous bone within 1.7 mm from the growth plates was excluded from the measurements 
in the vertebra. The image of the specimen, observed under a fluorescence microscope and 
recorded with a video camera (DK-3000; Hitachi), was processed using a plotter (Cosmozone 
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1SA; Nikon, Tokyo, Japan) to measure the parameters. For the femoral diaphysis, 20- to 
30-µm-thick cross-cut ground sections were obtained with a microgrinding machine system 
(KG4000; EXAKT, Norderstedt, Germany) and prepared for measurement. The image of the 
specimen, observed under a fluorescence microscope and recorded with a video camera, was 
processed using a plotter (Cosmozone 1SA; Nikon) to measure the total cross-sectional area. 
o 
Structural analysis using micro-computed tomography (micro-CT) 
  In order to investigate the effects of ALN and ELD combination therapy on the trabeculae 
in the cancellous tissue of the lumbar vertebral body, 3-dimensional trabecular analysis was 
performed by micro-CT (µCT 40; Scanco Medical, Zurich, Switzer- land). The µCT 40 is 
equipped with a microfocus X-ray tube with a focal spot of 10 µm, producing a fan beam that 
is detected by a charge-coupled device array with a turntable that can be shifted 
automatically in the axial direction. The filtered 40-kVp X-ray spectrum peaks at 25 keV, 
allowing excellent bone-versus-marrow contrast. The whole spinal body was scanned in 250 
slices (thickness, 13 µm) in the dorsoventral direction. On the original 3D images, 
morphometric indices were directly determined from the binarized volume of interest (VOI) 
(Augat et al. 1998). 
 
Statistical analysis 
  All data are presented as means±standard deviation (SD). Statistical analysis was 
performed by analysis of variance (ANOVA) on the SAS statistical analysis software 
package (SAS institute Inc., Cary, NC, USA). The statistical differences between individual 
groups were analyzed by ANOVA followed by Tukey's multiple comparison tests. The values 
of p<0.05 were considered significant for all statistical analyses. 
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Results 
 
The effect of combination therapy on bone mineral density and strength in lamber spine and 
femur midshaft 
  I invesitigated the effect of combination therapy of ALN and ELD on osteoporosis 
treatment using OVX rat model. After 12 weeks treatment of ALN and ELD, OVX rats were 
treated with ALN, ELD alone or their comination for 12 weeks and BMD of lumbar (L2-L4) 
which contains a lot of cancellous bone and femur (midshaft) which consist of cortical bone 
were measured using DXA. OVX rats treated with vehicle showed low BMD in both lumbar 
and femur midshaft compared to sham operated control rats. Rats with 12-weeks treatment 
of ALN or ELD alone showed significantly higher BMD than OVX treated with vehicle rats 
in both of lumbar spine and femur midshaft (Figure 6). The BMD of combination treatment 
of ALN and ELD group was much more higher than both mono-therapy groups in lumbar 
spine, and than ALN mono-therapy group in femur midshaft (Figure 6). Micro CT images of 
lumbar spine showed the reduction of cortical and cancellous bone reduction in OVX vehicle 
treated group (Figure 7).  The cross- and longitudinal-section of lumbar spine (L4) revealed 
that mono-therapy of ALN or ELD increased number of trabecular bone and cortical 
thickness. Moreover, the µCT images of lumber spine from rats got the combination 
treatment of ALN and ELD showed more solid structure of cancellous and cortical bone. 
(Figure 7). 
  A compresson test of lumbar spine was adopted to assess a bone strength of lumbar and 
3-point bending test to femur midshaft. The compression strength of lumbar spine in OVX 
vehicle treated group was significnatly decreased compared with sham operated group 
(Figure 8A). The max load of lumbar spine of ALN treated group showed tendency of 
restoration and significant increase in ELD treated group. A combination treatment of ALN 
and ELD showed significant increase in max load of lumbar than both mono-therapy groups. 
The OVX rats treated with vehicle appear to decline in femur bone strength compared to 
sham operated group and rats treated with ELD alone or combination treatment of ALN and 
ELD showed significantly increase of femur bone strength than OVX vehicle treatment rats. 
There are statistically significance between the femur bone strength of combination therapy 
group and each mono-therapy groups.   
 
The effect of combination treatment of ALN and ELD in bone turnover  
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  To elucidate the mechanisms of the effectiveness of combination treatment in BMD and 
bone strength of both lunbar spine and femur midshaft, I investigated the bone turnover of 
cancellous and cortical bone. The proportion of eroded surface (ES/BS) on lunbar cancellous 
bone was increased in OVX vehicle treated group than sham operated control group. Both 
mono-therapy groups exhibit significant decrease of ES/BS and combination treatment 
showed an additive effect on reduction of ES/BS in lumbar cancellous bone (Figure 9A). On 
femur cortical bone, ES/BS was not changed between sham, OVX, and mono-therapy groups 
but significantly decreased on combination therapy group compared to OVX group (Figure 
9B). Though the additive effect on reduction of bone resorption, combination treatment of 
ALN and ELD did not show an additive effect on the proportion of bone mineralizing surface 
of cancellous bone (Figure 9C). 
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Discussion 
 
  The different and complementary modes of action of anti-osteoporotic drugs allow a 
considerable range of combination therapies for treating osteoporosis. In chapter 2, I 
demonstrated that in an OVX rat model of osteoporosis, the combination treatment of ALN 
and ELD clearly improved the mechanical properties of the lumbar spine and midshaft 
femur by additively suppressing bone resorption while maintaining bone formation 
compared to each mono-therapy. Previous reports have demonstrated that the 
anti-resorptive effects of ALN and ELD are mediated through different pathways: BPs 
inhibit the bone resorptive capacity of mature osteoclasts and also may induce osteoclast 
apoptosis (Azuma et al. 1998), while active VD3 analogs reduce osteoclast number by 
suppressing osteoclast differentiation as I reported in chapter 1., ELD mono-therapy 
increased the mechanical properties as well as the BMD of the lumbar vertebrae and 
midshaft femur. Moreover, in agreement with previous studies (Black et al. 1996, Ito et al. 
2002, Sato et al. 1996, Ma et al. 2003), this study showed that prophylactic administration of 
ALN to OVX rats over a 12-week period could prevent estrogen depletion-induced bone loss 
in the femur and lumbar vertebrae by depressing the elevated bone turnover. 
Ovariectomized animals were widely used for the model of postmenopausal osteoporosis, so 
my data suggest that combination treatment of ALN and ELD may also have superior effect 
than mono-therapy in clinical use. The combination treatment of these drugs decreased bone 
resorption, which is the main effect of these drugs, whereas there was no significant 
difference in MS/BS, a bone formation parameter, compared to mono-therapy. Therefore, the 
present study suggested that the major mechanism underlying the anti-osteoporotic effect of 
ELD on vertebral cancellous bone and on the midshaft femur of OVX rats is induced by 
inhibiting bone resorption while maintaining bone formation.. 
  The detailed micro-CT analyses indicated that the increase in mechanical strength of the 
lumbar vertebra after ELD treatment was primarily due to the restoration of trabecular 
bone and the increase in thickness of cortical bone. The bone strength was affected not only 
BMD but also bone quality. It is considered that these morphological changes in cancellous 
and cortical bone may contribute to increase the bone strength by ALN and ELD 
combination treatment. As I mentioned, the combination treatment increased bone strength 
of femur. Bone fractures of femur in osteoporosis patients are risk for bedridden so that 
application of this combination treatment may improve QOL and life expectancy of 
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osteoporosis patients. These findings suggest that the combination treatment of ALN and 
ELD has a therapeutic advantage over either ALN or ELD mono-therapy for treating 
osteoporosis. 
  Based on my results, I concluded that with respect to the improvement of mechanical 
strength of the lumbar spine as well as the midshaft femur, the combination treatment of 
ALN and ELD was more beneficial than mono-therapy with either drug alone and the 
suppressive effect of ALN and ELD on bone resorption was considered to be additive, and 
the bone formation was not affected by ALN and ELD co-administration. 
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General discussion 
  Here, I demonstrated that the inhibitory effect of active VD3 on osteoclastogenesis. Active 
VD3 act to early osteoclast progenitor cells and upregulated the expression of IFN-β, which 
is a strong inhibitor for osteoclast differentiation. Some anti-bone resorptive drugs are used 
in osteoporosis treatment but main target of these drugs is mature osteoclast. So my data 
revealed that active VD3 has distinct mechanisms to regulate the osteoclast differentiation 
or its activity from other drugs using in osteoporosis treatment. This finding of new 
mechanism of anti-osteoclastogenesis effect of active VD3 may make advantage in 
investigation of effective osteoporosis treatment.  
  I also demonstrated the additive effect of ELD, an active VD3 analogue, and ALN, one of 
BPs, in OVX rats. The combination treatment these drugs showed additive effect on 
reduction of bone resorption, increasing BMD and bone strength. Moreover, though ELD 
and ALN combination treatment had additive effect on reduction of bone resorption, no 
effect was observed in bone formation compared to mono-therapy. Usually, too much 
suppression of bone resorption cause “freezing bone” characterized by no bone formation. 
This phenomenon thought to the cause of accumulation of bone micro-damage. It is 
considered that micro-damages of bone induce sudden bone fractures in femur midshaft 
which called “atypical fracture”. Atypical fractures in osteoporosis patients are hard to 
repair because of severe suppression of bone turnover. In this respect, ALN and ELD 
combination treatment has characteristic effect on controlling bone turnover from other 
osteoporosis treatment by suppression of bone resorption because strong inhibition of bone 
resorption usually accompanied with suppression of bone formation. 
  In conclusion, I revealed the novel mechanism of active VD3 in inhibition of 
osteoclastogenesis through IFN-β at the early stage. And also demonstrated that the 
combination treatment of ELD, an active VD3 analog, and ALN, one of BPs, which have 
different mechanisms in suppressing bone resorption, effectively inhibited bone resorption 
of OVX rats and increased BMD and bone strength both lumbar spine and femur midshaft. 
Though the combination therapy strongly reduced bone resorption in OVX rats, bone 
formation was not changed compared to sham operated rats or OVX rats treated with ALN 
or ELD alone. Based on my results, a clinical study of ALN and ELD combination treatment 
for osteoporosis patients is ongoing. It is expected that this regimen of strong inhibition of 
bone resorption with mild suppression of bone formation will help to reduce bone fractures 
and maintain QOL and life expectancy in osteoporosis patients.   
 26 
Acknowledgements 
I want to thank Dr. Kazuichi Sakamoto to supervise writing this article. I am deeply 
grateful to Dr. Takeshi Miyamoto, M.D. Hironari Takaishi, Dr. Yoshiteru Miyauchi, Dr. 
Kenichiro Matsuzaki, Dr. Hironori Kaneko to support research with human osteoclast 
precursor cells. Special thanks to Dr. Tadatsugu Taniguchi to provide IFN-β receptor KO 
mice. The research with OVX rats was performed with Dr. Ayako Shiraishi, Dr. Koichi Endo, 
Mr. Satoshi Takeda and Dr. Masahiko Mihara in Chugai-pharmaceutical Co., Ltd. 
Discussions with Dr. Mitsuru Furukawa, Dr. Toshio Suda, Dr. Yoshiaki Toyama, have been 
illuminating.  
 
 
 
 
 
 
 
 
 
  
 27 
References 
1. Aloia JF, Vaswani A, Yeh JK, Ellis K, Yasumura S, Cohn SH. (1988) Calcitriol in the 
treatment of postmenopausal osteoporosis. Am J Med. 84:401-8. 
2. Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak 
TW, Serfling E, Takayanagi H. (2005) Autoamplification of NFATc1 expression 
determines its essential role in bone homeostasis. J Exp Med. 202:1261-9. 
3. Augat P, Gordon CL, Lang TF, Iida H, Genant HK. (1998) Accuracy of cortical and 
trabecular bone measurements with peripheral quantitative computed tomography 
(pQCT). Phys Med Biol. 43:2873-83. 
4. Azuma Y, Oue Y, Kanatani H, Ohta T, Kiyoki M, Komoriya K. (1998) Effects of 
continuous alendronate treatment on bone mass and mechanical properties in 
ovariectomized rats: comparison with pamidronate and etidronate in growing rats. J 
Pharmacol Exp Ther. 286:128-35. 
5. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, 
Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud 
KE. (1996) Randomised trial of effect of alendronate on risk of fracture in women with 
existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 
348:1535-41. 
6. Demay MB, Kiernan MS, DeLuca HF, Kronenberg HM. (1992) Sequences in the human 
parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate 
transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci 
U S A. 89:8097-101. 
7. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, 
Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, 
Morrissey PJ, Peschon JJ, Schuh J. (1999) RANK is essential for osteoclast and lymph 
node development. Genes Dev. 13:2412-24. 
8. Erben RG, Weiser H, Sinowatz F, Rambeck WA, Zucker H. (1992) Vitamin D metabolites 
prevent vertebral osteopenia in ovariectomized rats. Calcif Tissue Int. 50:228-36. 
9. Erben RG, Bromm S, Stangassinger M. (1998) Short-term prophylaxis against estrogen 
depletion-induced bone loss with calcitriol does not provide long-term beneficial effects on 
cancellous bone mass or structure in ovariectomized rats. Osteoporos Int. 8:82-91. 
10. Fleisch H. (1998) Bisphosphonates: mechanisms of action. Endocr Rev. 19:80-100. 
11. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. (1979) 
 28 
Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and 
osteoporotic patients: effect of age and dietary calcium. J Clin Invest. 64:729-36. 
12. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 
3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. (1999) Effects of 
risedronate treatment on vertebral and nonvertebral fractures in women with 
postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With 
Risedronate Therapy (VERT) Study Group. JAMA. 282:1344-52. 
13. Ito M, Azuma Y, Takagi H, Komoriya K, Ohta T, Kawaguchi H. (2002) Curative effect of 
combined treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone loss by 
ovariectomy in aged rats. Jpn J Pharmacol. 89:255-66. 
14. Johnson RS, Spiegelman BM, Papaioannou V. (1992) Pleiotropic effects of a null 
mutation in the c-fos proto-oncogene. Cell. 71:577-86. 
15. Katsumata T, Nakamura T, Ohnishi H, Sakurama T. (1995) Intermittent cyclical 
etidronate treatment maintains the mass, structure and the mechanical property of bone 
in ovariectomized rats. J Bone Miner Res. 10:921-31. 
16. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, 
Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, 
Mak TW, Boyle WJ, Penninger JM. (1999) OPGL is a key regulator of osteoclastogenesis, 
lymphocyte development and lymph-node organogenesis. Nature. 397:315-23. 
17. Ma YL, Bryant HU, Zeng Q, Schmidt A, Hoover J, Cole HW, Yao W, Jee WS, Sato M. 
(2003) New bone formation with teriparatide [human parathyroid hormone-(1-34)] is not 
retarded by long-term pretreatment with alendronate, estrogen, or raloxifene in 
ovariectomized rats. Endocrinology. 144:2008-15. 
18. Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, 
Hayashi Y, Fukunaga M, Shiraki M, Nakamura T. (2005) A new active vitamin D, ELD, 
increases bone mass in osteoporotic patients under vitamin D supplementation: a 
randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 
90:5031-6. 
19. Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki 
M, Nakamura T. (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of 
osteoporotic fractures--a randomized, active comparator, double-blind study. Bone. 2011 
49:605-12. 
20. Matsuo K, Owens JM, Tonko M, Elliott C, Chambers TJ, Wagner EF. (2000) Fosl1 is a 
 29 
transcriptional target of c-Fos during osteoclast differentiation. Nat Genet. 24:184-7. 
21. Matsuo K, Galson DL, Zhao C, Peng L, Laplace C, Wang KZ, Bachler MA, Amano H, 
Aburatani H, Ishikawa H, Wagner EF. (2004) Nuclear factor of activated T-cells (NFAT) 
rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem. 279:26475-80. 
22. Miyamoto T, Suda T. (2003) Differentiation and function of osteoclasts. Keio J Med. 
52:1-7. 
23. Mosekilde L, Danielsen CC, Knudsen UB. (1993) The effect of aging and ovariectomy on 
the vertebral bone mass and biomechanical properties of mature rats. Bone. 14:1-6. 
24. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, 
Katsuki M, Yamamoto T, Inoue J. (1999) Severe osteopetrosis, defective interleukin-1 
signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 
4:353-62. 
25. Nakamura T, Imai Y, Matsumoto T, Sato S, Takeuchi K, Igarashi K, Harada Y, Azuma Y, 
Krust A, Yamamoto Y, Nishina H, Takeda S, Takayanagi H, Metzger D, Kanno J, 
Takaoka K, Martin TJ, Chambon P, Kato S. (2007) Estrogen prevents bone loss via 
estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell. 130:811-23. 
26. No authors listed (1991) Consensus development conference: prophylaxis and treatment 
of osteoporosis. Am J Med. 90:107-10.  
27. Okazaki T, Igarashi T, Kronenberg HM. (1988) 5'-flanking region of the parathyroid 
hormone gene mediates negative regulation by 1,25-(OH)2 vitamin D3. J Biol Chem. 
263:2203-8.  
28. Sairanen S, Kärkkäinen M, Tähtelä R, Laitinen K, Mäkelä P, Lamberg-Allardt C, 
Välimäki MJ. (2000) Bone mass and markers of bone and calcium metabolism in 
postmenopausal women treated with 1,25-dihydroxyvitamin D (Calcitriol) for four years. 
Calcif Tissue Int. 67:122-7. 
29. Sato M, Bryant HU, Iversen P, Helterbrand J, Smietana F, Bemis K, Higgs R, Turner 
CH, Owan I, Takano Y, Burr DB. (1996) Advantages of raloxifene over alendronate or 
estrogen on nonreproductive and reproductive tissues in the long-term dosing of 
ovariectomized rats. J Pharmacol Exp Ther. 279:298-305. 
30. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, 
Nakamura T, Matsumoto T, Ogata E. (2000) Alfacalcidol inhibits bone resorption and 
stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from 
estrogen. J Bone Miner Res. 15:770-9. 
 30 
31. Takahashi N, Kukita T, MacDonald BR, Bird A, Mundy GR, McManus LM, Miller M, 
Boyde A, Jones SJ, Roodman GD. (1989) Osteoclast-like cells form in long-term human 
bone marrow but not in peripheral blood cultures. J Clin Invest. 83:543-50. 
32. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, 
Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T. (2002a) Induction and 
activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in 
terminal differentiation of osteoclasts. Dev Cell. 3:889-901. 
33. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, Yokochi T, Oda H, 
Nakamura K, Ida N, Wagner EF, Taniguchi T. (2002b) RANKL maintains bone 
homeostasis through c-Fos-dependent induction of interferon-beta. Nature. 416:744-9. 
34. Uchiyama Y, HiguchI Y, Takeda S, Masaki T, Shira-Ishi A, Sato K, Kubodera N, Ikeda K, 
Ogata E. (2002) ELD, a vitamin D analog, is a more potent inhibitor of bone resorption 
than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Bone. 30:582-8. 
35. Villanueva AR. (1974) A bone stain for osteoid seams in fresh, unembedded, mineralized 
bone. Stain Technol. 49:1-8. 
36. Weber K, Goldberg M, Stangassinger M, Erben RG. (2001) 1alpha-hydroxyvitamin D2 is 
less toxic but not bone selective relative to 1alpha-hydroxyvitamin D3 in ovariectomized 
rats. J Bone Miner Res. 16:639-51. 
37. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, 
Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, 
Takahashi N, Suda T. (1998) Osteoclast differentiation factor is a ligand for 
osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. 
Proc Natl Acad Sci U S A. 95:3597-602. 
38. Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. (2010) Cohort 
profile: research on Osteoarthritis/Osteoporosis Against Disability study. Int J Epidemiol. 
39:988-95. 
39. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T, Suda T, Matsuo K. 
(2006) Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab. 
4:111-21.  
 31 
  
 
Figure 1 Signal transduction of RANKL induced osteoclastogenesis. RANKL binds to its  
receptor RANK and stimulates TRAF6 and c-Fos pathways. c-Fos not only accelerates but 
also inhibits osteoclastogenesis through expression of IFN-β secretion. Secreted IFN-β binds 
to its receptor in osteoclast and inhibits protein translation of c-Fos.  
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Figure 2 One-Alpha, 25-dihydroxy vitamin D3 (acrive VD3) inhibited osteoclast formation in 
colony-forming unit granulocyte macrophage (CFU-GM) cells. Human CFU-GM cells were 
cultured for 6 days with M-CSF (30 ng/ml) and receptor activator of nuclear factor kappa-B 
ligand (RANKL) (30 ng/ml) in the presence or absence of the indicated concentrations of 
active VD3. Mature osteoclasts were stained with TRAP (A) and the number of multinuclear 
osteoclasts were shown (B). (C) Acrive D3 was added in culture medium in indicated period. 
Cells were subjected to TRAP staining. Multinuclear TRAP-positive cells containing more 
than three nuclei were scored as osteoclasts. Vehicle, 0.1% EtOH. Data are mean number ± 
SD of osteoclasts (*P < 0.05, ***P < 0.001)  
Osteoclast differentiation of human CFU-GM cells
Human CFU-GM cells were seeded in 96-well plates
(2.0 9 104 cells/well) and cultured for 6 days in alpha-
minimum essential medium (a-MEM) supplemented with
10% FBS, 30 ng/ml M-CSF (Wako, Osaka, Japan) and
30 ng/ml RANKL (Wako) in the absence or presence of
10–10 M, 10–9 M, 10–8 M 1a,25(OH)2D3 (Wako). To
examine the role for IFN-b in osteoclastogenesis of human
CFU-GM cells, 500 unit/ml sheep polyclonal antibody
against human IFN-b (PBL Biomedical Laboratories, New
Brunswick, NJ, USA) was added in the culture medium.
The culture medium was changed to fresh medium every
other day. Osteoclastogenesis was evaluated by TRAP
staining as described below or pit formation assay as
described elsewhere [22, 23].
Tartrate-resistant acid phosphatase (TRAP) staining
Cultured cells were fixed with 10% formalin in PBS for
10 min at room temperature. After treatment with ethanol/
acetone (50:50 vol/vol) for 1 min, the well surface was air
dried and incubated for 30 min at room temperature with
TRAP-staining solution: 0.1 M sodium acetate (pH 5.0)
containing 0.01% naphthol AS-MX phosphate (Sigma-
Aldrich) as a substrate, and 0.03% red violet LB salt
(Sigma-Aldrich) as a stain for the reaction product in the
presence of 50 mM sodium tartrate. TRAP-positive
multinuclear cells containing more than three nuclei were
counted as osteoclasts.
RNA extraction, RT-PCR, and quantitative real-time
PCR analysis
Total RNA was isolated from osteoclast progenitors or
osteoclasts using an RNeasy Mini kit (Qiagen, Valencia,
CA, USA), and total RNA was reverse transcribed using
Reverscript IV (Wako). reverse transcription-polymerase
chain reaction (RT-PCR) analysis was performed using the
following primer sets: NFATc1, 50-TGT GCC GGA ATC
CTG AAA CT-30–50-GGC GGG AAG GTA GGT GAA
AC-30; c-Fos, 50-GGA CCT TAT CTG TGC GTGAAAC-
30–30-CAC ACT ATT GCC AGGAACACAG-50; IFN-b,
50-TCA TCT AGC ACTGGCTGG AA-30–30-TTTCAAAA
TCTTCTAGTGTCCTTTCA-50; b-actin, 50-TCC TGT
GGC ATC CAC GAAACTA-30–50-CTC GGC CAC ATT
GTGAACTTTG-30.
PCR reactions were performed using TITANIUM Taq
PCR Kit (Clontech, Mountain View, CA, USA). To
quantify transcripts, cDNA was subjected to real-time PCR
using Applied Biosystem 7500 Fastin Real-Time PCR
system (Applied Biosystems, Foster City, CA, USA) or a
Thermal Cycler Dice Real Time System (Takara Bio,
Otsu, Japan). Amplification of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) was used for sample normaliza-
tion. The probes and primers used were predesigned
Fig. 1 1-Alpha, 25-dihydroxy vitamin D3 (1a,25(OH)2D3) inhibits
osteoclast formation in colony-forming unit granulocyte macrophage
(CFU-GM) cells. Human CFU-GM cells were cultured for 6 days
with M-CSF (30 ng/ml) and receptor activator of nuclear factor
kappa-B ligand (RANKL) (30 ng/ml) in the presence or absence of
the indicated concentrations of 1a,25(OH)2D3. Cells were subjected
to TRAP staining (a, b) and pit formation assay (c). Multinuclear
TRAP-positive cells containing more than three nuclei were scored as
osteoclasts (b). Vehicle, 0.1% EtOH. Data are mean number ± SD of
osteoclasts (*P\ 0.05, ***P\ 0.001)
J Bone Miner Metab (2009) 27:643–652 645
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Figure 3 Interferon-beta (IFN-β) induced by 1α,25(OH)2D3 inhibits human 
osteoclastogenesis.  
Human CFU-GM cells were cultured with M-CSF (30 ng/ml) and RANKL (30 ng/ml) in the 
presence or absence of the indicated concentrations of 1α,25(OH)2D3 for 1–2 days. Then, 
total RNA was isolated and RT-PCR analysis was undertaken to detect the expression of 
IFN-β (A). β-actin expression is shown as an internal control. IFN-β expression was 
upregulated by active VD3 treatment in human osteoclast progenitor cells. V, vehicle (0.1% 
EtOH). Human CFU-GM cells were cultured with M-CSF (30 ng/ml) and RANKL (30 ng/ml) 
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in the presence or absence of 10–8 M active VD3 for 2 days. Total RNA was then isolated and 
real-time PCR analysis performed to detect the expression of IFN-β relative to GAPDH (B) 
(*P < 0.05). Human CFU-GM cells were cultured with M-CSF (30 ng/ml) and RANKL (30 
ng/ml) in the presence or absence of 10–8 M 1α,25(OH)2D3 with (black column) or without 
(white column) antibody against IFN-β for 6 days and stained with TRAP. Multinuclear 
TRAP-positive cells containing more than three nuclei were scored as osteoclasts (C). Left, 
representative data; right, data are mean number ± SD osteoclasts (**P < 0.01). 
Osteoclastogenesis inhibited by 10–8 M acitive VD3 was significantly rescued by the antibody 
against IFN-β. Vehicle, 0.1% EtOH. 
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Figure 4 IFN-α/β receptor 1-dependent inhibition of osteoclastogenesis by active VD3. 
Osteoclast progenitor cells isolated from wild-type (white column) or IFNAR-deficient (black 
column) mice were cultured with M-CSF (30 ng/ml) and RANKL (30 ng/ml) in the presence 
or absence of the indicated concentrations of active VD3 for 5 days and stained with TRAP. 
Multinuclear TRAP-positive cells containing more than three nuclei were scored as 
osteoclasts. Data are mean number ± SD of osteoclasts (**P ¥<0.01, ***P ¥<0.001). V, 
vehicle, 0.1% EtOH. 
  
Discussion
The clinical effects of 1a,25(OH)2D3 analogues have been
considered to occur via correction of vitamin D deficiency
in osteoporotic patients. However, a recent study reported
that administration of 1a,25(OH)2D3 analogues to osteo-
porosis patients under vitamin D supplementation also
increased BMD [25], suggesting that 1a,25(OH)2D3 ana-
logues have antiosteoporotic effects in addition to correc-
tion of vitamin D deficiency. Here we provide a possible
mechanism underlying the antiosteoporotic effect of
1a,25(OH)2D3 in which 1a,25(OH)2D3 inhibits osteo-
clastogenesis by upregulating IFN-b expression, which in
turn inhibits the expression of NFATc1, an essential tran-
scription factor for osteoclast differentiation.
1a,25(OH)2D3 downregulates PTH transcription in
parathyroid cells [2, 3] and upregulates intestinal calcium
absorption, thereby preventing BMD reduction [1]. In spite
of its usage for osteoporosis therapy in humans, it was
reported that 1a,25(OH)2D3 is an osteoclast-inducing factor
in human cells [26]. 1a,25(OH)2D3 has also been used as
an osteoclastogenesis-stimulating agent in cocultures of
murine osteoclast precursor cells with calvarial osteoblasts.
1a,25(OH)2D3 upregulates RANKL and downregulates the
expression of OPG in osteoblasts [10], and this reciprocal
regulation of RANKL and OPG is critical for osteo-
clastogenesis. Thus, 1a,25(OH)2D3 has been considered to
be an osteoclast-inducing factor through osteoblast-medi-
ated activity. The regulation of the balance between direct
inhibition of osteoclast progenitor cells by 1a,25(OH)2D3
and indirect stimulation of osteoclastogenesis through
osteoblasts is still unclear, but our results suggest that
administration of 1a,25(OH)2D3 or its analogues to osteo-
porosis patients could directly inhibit osteoclastogenesis in
circumstances with high bone turnover rates. Because we
could not find any putative vitamin D response elements in
50-flanking region of the IFN-b gene, the regulation of IFN-
b expression by 1a,25(OH)2D3 is likely indirect. Further
study is needed to elucidate the molecular mechanisms of
the regulation of IFN-b expression by 1a,25(OH)2D3.
Several differences have been reported between mouse
and human osteoclastogenesis; granulocyte macrophage
colony-stimulating factor (GM-CSF) accelerates osteoclast
differentiation and osteolytic bone metastasis of human
breast cancer [27], but completely inhibits osteoclasto-
genesis in mouse bone marrow cells through the down-
regulation of c-Fos [28]. Therefore, analysis in human cells
would be required in developing antihuman osteoclast
therapies.
c-Fos, a member of the AP-1 transcription factor family,
is one of the key osteoclastogenesis molecules induced by
M-CSF and RANKL, and c-Fos-deficient mice exhibit
osteopetrosis because of a complete lack of osteoclast
differentiation. NFATc1 is a downstream target of c-Fos
and is also an essential transcription factor for osteoclast
differentiation [14, 16, 17], and thus c-Fos and NFATc1
cooperatively regulate osteoclast differentiation. Although
several differences in osteoclastogenesis may occur
between humans and mice, both c-Fos and NFATc1 might
be essential for osteoclastogenesis in both human and
mouse systems.
The physiological serum concentration of 1a,25(OH)2D3
has been reported to be approximately 0.1 nM; however, the
administration of 1a,25(OH)2D3 or its analogues such as
Fig. 6 IFN-a/b receptor 1-dependent inhibition of osteoclastogenesis
by 1a,25(OH)2D3. a Osteoclast progenitor cells isolated from wild-
type (white column) or IFNAR-deficient (black column) mice were
cultured with M-CSF (30 ng/ml) and RANKL (30 ng/ml) in the
presence or absence of the indicated concentrations of 1a,25(OH)2D3
for 5 days and stained with TRAP. Multinuclear TRAP-positive cells
containing more than three nuclei were scored as osteoclasts. Data are
mean number ± SD of osteoclasts (**P\ 0.01, ***P\ 0.001). V,
vehicle, 0.1% EtOH. b Osteoclast progenitor cells isolated from wild-
type (WT) or IFNAR-deficient (IFNARI KO) mice were cultured with
M-CSF (30 ng/ml) and RANKL (30 ng/ml) in the presence or
absence of 10–8 M 1a,25(OH)2D3 for the indicated period, and
Western blot analysis was performed to detect c-Fos and actin protein
650 J Bone Miner Metab (2009) 27:643–652
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Figure 5  Active VD3 act to osteoclast progenitor cells and upregulated IFN-β expression 
and inhibited osteoclastogenesis.  
Osteoclast precursor cells were stimulated with active VD3 for 2 days with SCF, GM-CSF 
and IL-3. Then active VD3 and cytokines were washed out and osteoclastogenesis was 
induced by M-CSF and RANKL. Osteoclasts were visualized by TRAP staining (A). Active 
VD3 stimulation to osteoclast precursor cells inhibited osteoclastogenesis. Number of TRAP 
positive multinuclear cells were shown (B). mRNA of IFN-β was increased in osteoclast 
precursor cells after 2-day’s activeVD3 stimulation (C). 
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Figure 6  The bone mineral density (BMD) measured by dual-energy X-ray absorptiometry 
in the Lumber spine (L2-L4) (A) and the middle femur (B) after treatment with ELD and 
ALN, alone or in combination for 12 weeks in OVX rats. Each column and vertical bar 
represents the mean ± SD.***: p < 0.001 vs. OVX control group; ccc: p < 0.001 vs. 
mono-therapy. The statistical differences between individual groups were analyzed by 
ANOVA followed by Tukey's multiple comparison tests. 
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Figure 7  Micro-CT images of lumbar vertebra (L4) in ovariectomized (OVX) rats treated 
with eldecalcitol (ELD) and alendronate (ALN), alone or in combination. ALN or ELD alone 
prevented the bone loss and deterioration of cancellous bone structure induced by OVX. 
Note that co-administration of ALN and ELD improved the density of the trabecular bone 
network and thickened the cortical region of vertebral bodies. 
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Figure 8  A bone strength of lumber spine (L5)(A)and the middle femur (B) after treatment 
with eldecalcitol (ELD) and alendronate (ALN), alone or in combination, for 12 weeks in 
ovariectomized (OVX) rats. Each column and vertical bar represents the mean ± SD.***: p < 
0.001 vs. OVX control group; c:p < 0.05 vs. mono-therapy ;ccc: p < 0.001 vs. mono-therapy. 
The statistical differences between individual groups were analyzed by ANOVA followed by 
Tukey's multiple comparison tests.  
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Figure 9 Bone formation and resorption parameters. ES/BS in L3 and endosteal of femur 
midshaft and MS/BS in lumbar are shown. Each column and vertical bar represents the 
mean ± SD.***: p < 0.001 vs. OVX control group;ccc: p < 0.001 vs. mono-therapy. The 
statistical differences between individual groups were analyzed by ANOVA followed by 
Tukey's multiple comparison tests.  
 
0"
5"
10"
15"
20"
25"
30"

***
*** ***
***


**"p<0.01,""***"p<0.001"""vs""OVX"
ccc""p<0.001""vs""ALN+ELD 
ES/BS"(L3)"
0"
5"
10"
15"
20"
25"
30"
35"
40"
45" 
***
ES/BS"(endosteal)"
"""Sham""""""""""""OVX""""""""""""OVX""""""""""""""OVX"""""""""""""""OVX"
""""";""""""""""""""";""""""""""ALN""""""""""""";""""""""""""""ALN"
""""";""""""""""""""";"""""""""""""";"""""""""""""ELD"""""""""""ELD
"""""Sham""""""""""""OVX""""""""""""OVX""""""""""""""OVX""""""""""""""OVX"
""""""";""""""""""""""";""""""""""ALN""""""""""""";"""""""""""""ALN"
""""""";""""""""""""""";"""""""""""""";"""""""""""""ELD"""""""""""ELD
Sakai"et.al."Bone."2012"50(5):1054F63
"""Sham"" OVX" OV OVX OVX
""""";"""""""";""""""ALN""""";""""""ALN"
""""";"""""""";"""""""";"""""ELD""""ELD
"""S am"""" VX"""""OVX"""" VX"""""OVX"
""""";"""""""";""""""ALN""""";""""""ALN"
""""";"""""""";"""""""";"""""ELD""""ELD
A B
(%) (%)
	
!
ALNELD
0!
5!
10!
15!
20!
25!
30!
SHAM% OVX% ALNH% EDL% ALNHEDL%
ES/BS!(L3)!(%)!
0!
5!
10!
15!
20!
25!
30!
35!
SHAM% OVX% ALNH% EDL% ALNHEDL%
MS/BS!(L3)!(%)!
!!!!!Sham!!!!!!!!!!OVX!!!!!!!!!!!!!OVX!!!!!!!!!!!!OVX!!!!!!!!!!!!!OVX!
!!!!!!!9!!!!!!!!!!!!!!!!9!!!!!!!!!!!!!ALN!!!!!!!!!!!!9!!!!!!!!!!!!!!ALN!
!!!!!!!9!!!!!!!!!!!!!!!!9!!!!!!!!!!!!!!!!9!!!!!!!!!!!!ELD!!!!!!!!!!!!ELD
!!!!!Sham!!!!!!!!!!OVX!!!!!!!!!!!!!OVX!!!!!!!!!!!!OVX!!!!!!!!!!!!!OVX!
!!!!!!!9!!!!!!!!!!!!!!!!9!!!!!!!!!!!!!ALN!!!!!!!!!!!!9!!!!!!!!!!!!!!ALN!
!!!!!!!9!!!!!!!!!!!!!!!!9!!!!!!!!!!!!!!9!!!!!!!!!!!!!!!ELD!!!!!!!!!!ELD
***
***p<0.001%%%vs%%OVX%
ccc%p<0.001%%vs%%ALN+ELD 
*** ***
***


*** *** ***
***
!!! m!!!! X!!!!!!OV !!!!!!OV !!!!!!!OV !
!!!!!9!!!!!!!!9!!!!!!ALN!!!!!!9!!!!!!!!ALN!
!!!!!9!!!!!!!!9!!!!!!!!9!!!!!!!ELD!!!!!ELD
!!!Sham!!!!OVX!!!!!!OVX!!!!!!OVX!!!!!!!OVX!
!!!!!9!!!!!!!!9!!!!!!ALN!!!!!!9!!!!!!!!ALN!
! 9 9! 9! ELD!! ELD
C
(%)
